Want to join the conversation?
$ABBV said Imbruvica is tracking in line to slightly ahead of its expectations, following its approval for first-line use in chronic lymphocytic leukemia. Imbruvica has achieved the number one market share position in all approved disease indications in second-line and second-line plus treatment.
Visa ($V) set to release it earning after market close today. With new CEO resigning so close to the earnings, should we expect to see any surprises? Visa has been making strong moves with Visa Europe acquisition, partnership with PayPal and a 15% increase if quarterly dividends.
Kimberly Clark Corp ($KMB) has been in decline for most of the year, the stock has also not been getting any analyst love. Will today’s earnings break the trend? Revenue has been up and down in the last four quarters, let us see what this quarter brings.
$KMB down close to 4% after it misses on earnings and revenue. Forecasts are lower for the year.